PE Tech Report


Like this article?

Sign up to our free newsletter

M2i secures EUR12m funding from Idinvest Partners

Idinvest Partners has secured EUR12 million in funding for life sciences company M2i as part of the firm’s continued support of high-growth European SMEs.

The funds raised will enable biocontrol producer M2i to finance the approval process of its Biocontrol products, pursue its R&D investment strategy and accelerate its international development.
M2i Life Sciences is a world leader in the field of pheromones for crop protection, animal health and human health, producing agricultural chemical products in the Biocontrol sector. Addressing the issue of tackling increasing resistance and toxicity of insecticides and GMOs, the company provides innovative alternative solutions for all methods of biological protection.
Matthieu Baret, Partner at Idinvest, says: “This investment comes from the Idinvest Growth Fund II which targets small-mid cap companies that have the potential to expand globally and become industry leaders within the Digital, Health and Smart Cities sectors.” Following a first close of 250 million euros at the end of 2016, Idinvest is targeting between 350 and 400 million euros for a final close in 2017. Since its launch 6 months ago, the fund has invested in three European SMEs, Vestiaire Collective, an online marketplace for luxury goods and IoT business Actility. 
Emmanelle Pierret, Investment Director at Idinvest Partners, says: “M2i provides an unprecedented response to the challenges of respecting the environment and protecting biodiversity. The effectiveness of their products has already been demonstrated, in particular on field crops that have not yet been equipped with Biocontrol solutions, and we are very happy to be supporting them in their next stage of growth.”
Philippe Guerret, President of M2i group, adds: “Over four years, M2i has built a vast range of solutions for a profitable, sustainable and environmentally friendly agriculture. This partnership with Idinvest will allow us to continue to commercially deploy these solutions at an even faster pace, and also continue to expand our portfolio.”  

Like this article? Sign up to our free newsletter